The DCGI has said the approval is in “clinical trial mode†but has not clarified this in detail. If an experimental vaccine is given to people, there should be informed consent explaining the potential risks and benefits of the vaccine and post-vaccination follow-up. In case there is any serious adverse reaction, the recipient may also be eligible for compensation.Explained: Why conditional approval for Bharat Biotech’s Covaxin is raising questions
The DCGI has said the approval is in “clinical trial mode†but has not clarified this in detail. If an experimental vaccine is given to people, there should be informed consent explaining the potential risks and benefits of the vaccine and post-vaccination follow-up. In case there is any serious adverse reaction, the recipient may also be eligible for compensation.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment